Literature DB >> 31833260

The basic principles of oncologic surgery during minimally invasive radical hysterectomy.

Christhardt Köhler1,2, Achim Schneider3,4, Simone Marnitz5, Andrea Plaikner6.   

Abstract

Entities:  

Year:  2020        PMID: 31833260      PMCID: PMC6918880          DOI: 10.3802/jgo.2020.31.e33

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


× No keyword cloud information.
Patients with early cervical cancer can be treated either by surgery or by chemoradiation [1]. International guidelines recommend treatment by one oncologic modality rather than combined therapy to avoid treatment-related toxicity (European Society of Gynaecological Oncology, National Comprehensive Cancer Network) [23]. Consequently, pretreatment decision for one of these treatment options has to be made by an interdisciplinary tumor board council. Indeed, this recommendation reflects not only tumor-stage and histology-related factors but also “unspoken” arguments like surgical skills, national traditions, availability of radiation oncology and others. Moreover, best treatment for patients with tumor stages IB (±lymphovascular invasion) ≥4 cm, IIA and IIB is not defined yet, that opens the door for a wide spectrum of different strategies. Patients with these potentially operable stages are often undergo adjuvant chemoradiation (up to 85%) according to Peters et al. [4] or Sedlis et al.'s criteria [5], whereas primary chemoradiation could be a single treatment alternative [6]. High-risk features for adjuvant chemoradiation are known as lymph-node positivity, parametrial involvement and R1/R2-resection. Lymph node metastases can be confirmed or excluded with high accuracy by intraoperative frozen section and consequently radical hysterectomy can be continued or abandoned. Transvaginal creation of a tumor-adapted vaginal cuff in iodine-positive area is an ideal tool to avoid vaginal tumor involvement. The most problematic parameter preoperatively is parametrial spread. In accordance to a previously published study by Kong et al. [7] and Woo et al. [8] could demonstrate a pooled sensitivity and specificity of 0.73 and 0.93 for the detection of parametrial invasion. Radical hysterectomy is the state-of-the-art surgery for patients with early cervical cancer. A standardized surgical approach with curative intent was defined in the last century in Vienna. Whereas Schauta [9] used a transvaginal approach, his disciple, Wertheim [10] propagated a transabdominal route. Both techniques underwent several modifications over the next decades and with the advent of laparoscopic surgery the advantages of an abdominal and transvaginal access could be combined [1112]. Thereafter a historical change and onco-surgical tragedy occurred: gynecologic surgeons renounced the transvaginal part of radical hysterectomy completely, the main reason being lack of training in vaginal surgery [131415]. Up to that point the principles of oncologic hygiene were guaranteed by sealing off all tumor cells using transvaginal sutures as initially described by Schauta [9]. Now laparoscopic surgeons inserted transtumoral manipulators and performed transabdominal colpotomy exposing the pelvic peritoneum to vital tumor cells, a procedure never recommended by Wertheim (Table 1) [910111215161718].
Table 1

Use of transtumoral manipulators and tumor sealing-off according to procedure method

MethodRelationSealing off tumorTranstumoral manipulatorReferences
Radical abdominal HEAbdYes - transabdominal clampNoWertheim [10]
Radical vaginal HEVagYes - transvaginal suturesNoSchauta [9]
LARVHVag - LapYes - transvaginal suturesNoDargent et al. [11], Hertel et al. [16]
VALRHLap - VagYes - transvaginal suturesNoKoehler et al. [12]
TLRHLapNo - intracorporeal colpotomyYesRamirez et al. [17], Melamed et al. [18]
RRHRoboticNo - intracorporal colpotomyYesSert et al. [15], Ramirez et al. [17]

Abd, abdominal; Lap, laparoscopic; LARVH, laparoscopic-assisted radical vaginal hysterectomy; RRH, robotic right hemicolectomy; TLRH, total laparoscopic hemicolectomy; Vag, vaginal; VALRH, vaginal-assisted laparoscopic radical hysterectomy.

This obvious lack of oncologic hygiene was no obstacle for the propagation of laparoscopic radical hysterectomy since the obvious advantages of laparoscopic surgery such as minimal invasiveness, easy preservation of autonomic nerves, bloodless dissection and quick recovery were advantageous for the patients [131415]. Fortunately for future patients a prospective randomized trial (Laparoscopic Approach to Cervical Cancer; LACC) was performed which showed a significant higher disease-free survival for women after open abdominal surgery as compared to laparoscopic or robotic surgery (99% vs. 94%) [17]. This cornerstone trial brought down the existing opinion of oncologic equivalency of minimal-invasive radical hysterectomy and abdominal radical hysterectomy. Further studies confirmed LACC results [18]. Resulting discomfiture and disbeliefs among gynecologic oncologists worldwide have been addressed in many editorials and comments, trying to explain the unexpected results [19]. Many possible arguments for minimally-invasive inferiority have been debated as different radicality, smaller vaginal cuff, ethnic differences, tumor size as selection criteria, robotic versus straight stick laparoscopy, learning curves, different schools of surgery, data completeness and video review in LAAC trial, circulating CO2, use of intratumoral manipulators, etc. In our answer to the results of LACC, we collected prospectively actual data on consecutive 389 patients who underwent combined vaginal-laparoscopic radical hysterectomy with a median follow-up period of 10 years [20]. These patients had a risk profile comparable to the LACC cohort and their recurrence free survival rate is identical to the patients who underwent open surgery in LACC (98.5%). These results can be achieved by avoiding manipulator and transvaginal closure to seal off the cervical cancer cells. Preliminary results from other studies (NCT03958305) support this theory. These findings are now corroborated by the study of Kong et al. [21]. Authors have evaluated the oncologic outcome of patients with early-stage cervical cancer who underwent minimally invasive radical hysterectomy before and after the application of parametrial invasion criteria defined as disruption of the cervical stroma ring on MRI scans, and patients with intracorporal or vaginal colpotomy. In agreement with Kong et al. [21] we conclude that patients with early parametrial involvement visible in high solution MRI should rather undergo laparoscopic staging followed by primary chemoradiation [22]. In patients without parametrial spread that undergo laparoscopic or robotic radical hysterectomy transabdominal intracorporeal colpotomy must be avoided and use of any uterine manipulators should be forbidden. The announced Chinese phase III randomized multicentric trial will prove again if minimally invasive radical hysterectomy is equivalent to open radical hysterectomy and also addresses use of uterine manipulators [23].
  20 in total

1.  From laparoscopic assisted radical vaginal hysterectomy to vaginal assisted laparoscopic radical hysterectomy.

Authors:  C Koehler; E Gottschalk; V Chiantera; S Marnitz; K Hasenbein; A Schneider
Journal:  BJOG       Date:  2011-11-15       Impact factor: 6.531

2.  Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff - a multicenter analysis.

Authors:  Christhardt Kohler; Hermann Hertel; Jörg Herrmann; Simone Marnitz; Peter Mallmann; Giovanni Favero; Andrea Plaikner; Peter Martus; Mieczyslaw Gajda; Achim Schneider
Journal:  Int J Gynecol Cancer       Date:  2019-06       Impact factor: 3.437

Review 3.  Magnetic resonance imaging for detection of parametrial invasion in cervical cancer: An updated systematic review and meta-analysis of the literature between 2012 and 2016.

Authors:  Sungmin Woo; Chong Hyun Suh; Sang Youn Kim; Jeong Yeon Cho; Seung Hyup Kim
Journal:  Eur Radiol       Date:  2017-07-19       Impact factor: 5.315

Review 4.  Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.

Authors:  Kathryn P Pennington; Renata R Urban; Heidi J Gray
Journal:  J Natl Compr Canc Netw       Date:  2019-01       Impact factor: 11.908

5.  Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study.

Authors:  J-H Nam; J-Y Park; D-Y Kim; J-H Kim; Y-M Kim; Y-T Kim
Journal:  Ann Oncol       Date:  2011-08-12       Impact factor: 32.976

6.  Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial.

Authors:  Christhardt Köhler; Alexander Mustea; Simone Marnitz; Achim Schneider; Vito Chiantera; Uwe Ulrich; Jens-Peter Scharf; Peter Martus; Marcelo Andrade Vieira; Audrey Tsunoda
Journal:  Am J Obstet Gynecol       Date:  2015-05-15       Impact factor: 8.661

7.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

8.  Laparoscopic-assisted radical vaginal hysterectomy (LARVH): prospective evaluation of 200 patients with cervical cancer.

Authors:  Hermann Hertel; Christhardt Köhler; Wolfgang Michels; Marc Possover; Roberto Tozzi; Achim Schneider
Journal:  Gynecol Oncol       Date:  2003-09       Impact factor: 5.482

9.  Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.

Authors:  Alexander Melamed; Daniel J Margul; Ling Chen; Nancy L Keating; Marcela G Del Carmen; Junhua Yang; Brandon-Luke L Seagle; Amy Alexander; Emma L Barber; Laurel W Rice; Jason D Wright; Masha Kocherginsky; Shohreh Shahabi; J Alejandro Rauh-Hain
Journal:  N Engl J Med       Date:  2018-10-31       Impact factor: 91.245

10.  Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer.

Authors:  B M Sert; J F Boggess; S Ahmad; A L Jackson; N M Stavitzski; A A Dahl; R W Holloway
Journal:  Eur J Surg Oncol       Date:  2016-01-21       Impact factor: 4.424

View more
  6 in total

1.  Laparoscopic nerve-sparing radical hysterectomy without uterine manipulator for cervical cancer stage IB: description of the technique, our experience and results after the era of LACC trial.

Authors:  Andreas Kavallaris; Nektarios Chalvatzas; Antonios Gkoutzioulis; Dimitrios Zygouris
Journal:  Arch Gynecol Obstet       Date:  2020-10-17       Impact factor: 2.344

Review 2.  Minimally Invasive Surgery for Cervical Cancer in Light of the LACC Trial: What Have We Learned?

Authors:  Omar Touhami; Marie Plante
Journal:  Curr Oncol       Date:  2022-02-14       Impact factor: 3.677

3.  Clinical effects of cervical conization with positive margins in cervical cancer.

Authors:  Yukari Nagao; Akira Yokoi; Kosuke Yoshida; Masanori Sumi; Masato Yoshihara; Satoshi Tamauchi; Yoshiki Ikeda; Nobuhisa Yoshikawa; Kimihiro Nishino; Kaoru Niimi; Hiroaki Kajiyama
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

4.  Effect of Quality Control Program in Surgical Management of Early Cervical Cancer.

Authors:  Ji Eun Shim; Mi-Kyung Kim; Yun Hwan Kim; Seung Cheol Kim
Journal:  J Korean Med Sci       Date:  2021-11-22       Impact factor: 2.153

5.  Efficacy of different surgical approaches on survival outcomes in patients with early-stage cervical cancer: protocol for a multicentre longitudinal study in China.

Authors:  Xiaopei Chao; Ming Wu; Shuiqing Ma; Xianjie Tan; Sen Zhong; Xiaochen Song; Lei Li
Journal:  BMJ Open       Date:  2020-08-20       Impact factor: 2.692

6.  Retrospective Analysis of Cervical Cancer Treatment Outcomes: Ten Years of Experience with the Vaginal Assisted Radical Laparoscopic Hysterectomy VARLH.

Authors:  R Wojdat; E Malanowska
Journal:  Biomed Res Int       Date:  2022-01-10       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.